

## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 1 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

以下測試之樣品係由申請廠商所提供及確認：

產品名稱： 極效水潤玉手霜 ULTRA-MOISTURE HAND CREAM  
申請廠商： 生麗國際股份有限公司  
申請廠商地址： 桃園市桃園區中正路1353號15樓  
電話/聯絡人： 03-2151011 / 生麗國際股份有限公司  
樣品包裝： 請參考報告末頁樣品照片  
數量： 4 pcs  
樣品保存方式： 室溫  
產品型號： ---  
產品批號： PCP016002  
製造/國內負責廠商： 生麗國際股份有限公司  
製造日期： 2022.01.13  
有效期限： 2025.01.12  
收樣日期： 2022年04月22日  
測試日期： 2022年04月22日 ~ 2022年05月11日

測試結果： -請見下頁-

陳新智

陳新智 經理  
台灣檢驗科技股份有限公司  
報告簽署人



## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 2 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 測試結果：

測試項目	CAS NO.	測試方法	測試結果	定量/偵測極限	單位
365項西藥定性分析	---	---	---	---	---
本樣品檢測共365項西藥定性分析(項目詳見附錄)		本測試依實驗室內部方法(TESP-UB-0173, TESP-UB-0181, TESP-UB-0182), 以薄層層析法(TLC), 液相層析離子阱質譜儀(LC/MS/MS)或氣相層析質譜儀(GC/MS)檢測。	N.D.	---	ppm(µg/g)

### 備註：

1. 測試報告僅就委託者之委託事項提供測試結果，不對產品合法性做判斷。
2. 本測試報告之所有檢驗內容，均依委託事項執行檢驗，如有不實，願意承擔完全責任。
3. 本報告不得分離，分離使用無效。
4. 若該測試項目屬於定量分析則以「定量極限」表示；若該測試項目屬於定性分析則以「偵測極限」表示。
5. 低於定量極限/偵測極限之測定值以「N.D.」或「陰性」表示。微生物測試低於定量極限以「<定量極限值」表示。

- END -

## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 3 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
2,4-Dinitrophenol	51-28-5	3600	Benzathine-penicillin	41372-02-5	3300
2-Diphenylmethylpyrrolidine	22348-31-8	900	Benzbromarone	3562-84-3	900
7-keto-Dehydroepiandrosterone	566-19-8	3000	Benzhexol	144-11-6	1800
Acetaminophen	103-90-2	300	Benzocaine	94-09-7	300
Acetil acid	147676-78-6	1500	Benzylamine	642-72-8	348
Acetildenafil	831217-01-7	600	Betamethasone	378-44-9	900
Acetohexamide	968-81-0	750	Betamethasone 21 Acetate	987-24-6	4500
Acetophenetidin	62-44-2	3600	Betamethasone Benzoate	22298-29-9	3225
Acetylvardenafil	1261351-28-3	600	Betamethasone Dipropionate	5593-20-4	1050
Acrinol	1837-57-6	2832	Betamethasone Valerate	2152-44-5	108
Allopurinol	315-30-0	600	Bezafibrate	41859-67-0	600
Ambroxol	18683-91-5	600	Bisacodyl	603-50-9	600
Aminophylline	317-34-0	4500	Bisoprolol Fumarate	104344-23-2	60
Aminopyrine	58-15-1	900	Bromhexine	3572-43-8	1200
Aminotadalafil	385769-84-6	900	Bromopride	4093-35-0	60
Amitriptyline	549-18-8	750	Brompheniramine	86-22-6	1800
Amlodipine	88150-42-9	300	Bromvalerylurea	496-67-3	1950
Amoxicillin	26787-78-0	4320	Bucetin	1083-57-4	600
Amphetamine	300-62-9	375	Bufexamac	2438-72-4	1650
Ampicillin	69-53-4	2700	Buspiron	36505-84-7	3600
Apomorphine	58-00-4	600	Butropium	107080-63-7	3000
Aspirin	50-78-2	600	Caffeine	58-08-2	600
Astemizole	68844-77-9	150	Camyllofine	54-30-8	3000
Atenolol	29122-68-7	300	Carbamazepine	298-46-4	3600
Atorvastatin	134523-00-5	420	Carbetapentane	77-23-6	150
Atropine	51-55-8	150	Carbimazole	22232-54-8	600
Avanafil	330784-47-9	600	Carbinoxamine	486-16-8	1650
Baclofen	1134-47-0	300	Carbodenafil	944241-52-5	1500
Barbital	57-44-3	750	Carisoprodol	78-44-4	375
Benazepril	86541-75-5	450	Carvedilol	72956-09-3	2400
Benproperine	2156-27-6	600	Cefamandole nafate	42540-40-9	150

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 4 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Cefazolin	25953-19-9	1050	Cloperastine	3703-76-2	1500
Cefoperazone dihydrate	113826-44-1	300	Clotrimazole	23593-75-1	3000
Cefotaxime	63527-52-6	150	Cloxacillin Sodium	7081-44-9	4770
Ceftriaxone	73384-59-5	4224	Clozapine	5786-21-0	600
Celecoxib	169590-42-5	900	Cocaine	50-36-2	750
Cephalexin	15686-71-2	75	Colchicine	64-86-8	750
Cephradine	38821-53-3	81	Cortisone	53-06-5	750
Cetilistat	282526-98-1	1500	Cortisone acetate	50-04-4	3600
Cetirizine	83881-51-0	159	Cyproheptadine	129-03-3	1500
Chloramphenicol	56-75-7	1200	Desacetyl bisacodyl	603-41-8	600
Chlordiazepoxide	58-25-3	300	Desacetyl diltiazem	42399-40-6	60
Chlorhexidine	55-56-1	2400	Dexamethasone	50-02-2	1200
Chlormezanone	80-77-3	60	Dexamethasone phosphate	312-93-6	900
Chloropretadalafil	171489-59-1	1500	Dextromethorphan	125-71-3	1500
Chlorothiazide	58-94-6	750	Diazepam	439-14-5	300
Chlorpheniramine	113-92-8	1200	Dibucaine	85-79-0	450
Chlorpromazine	50-53-3	300	Diclofenac	15307-86-5	600
Chlorpropamide	94-20-2	600	Dicyclomine	77-19-0	375
Chlortetracycline	57-62-5	600	Diethylpropion	39648-50-5	450
Chlorzoxazone	95-25-0	1050	Diethylstilbestrol	56-53-1	600
Cimetidine	51481-61-9	1500	Difloxacin	98106-17-3	3000
Cinnarizine	298-57-7	600	Digitoxin	71-63-6	450
Ciprofloxacin(CFA)	85721-33-1	240	Dihydroergotamine	511-12-6	150
Clenbuterol	21898-19-1	900	Diltiazem	42399-41-7	300
Clindamycin HCl	21462-39-5	456	Dimenhydrinate	523-87-5	150
Clindamycin phosphate	24729-96-2	150	Dimethylsildenafil	496835-35-9	3000
Clobenzorex	13364-32-4	375	Dimetridazole	551-92-8	150
Clobetasol Propionate	25122-46-7	2400	Diphenhydramine	58-73-1	375
Clofibrate	637-07-0	1500	Diphenylhydantoin	57-41-0	150
Clonazepam	1622-61-3	150	Diprophylline	479-18-5	900
Clonidine	4205-90-7	300	Dipyridamole	58-32-2	450

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 5 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Dipyron	68-89-3	600	Fluocinonide	356-12-7	3600
Dithio-desmethyl-carbodenafil	1333233-46-7	1500	Fluoxetine	54910-89-3	1200
Doxazosin	74191-85-8	2400	Fluoxymesterone	76-43-7	600
Doxycycline	564-25-0	576	Flurbiprofen	5104-49-4	150
Doxylamine	469-21-6	60	Fluvastatin	93957-54-1	1200
Dyclonine Hydrochloride	536-43-6	3600	Furosemide	54-31-9	600
Econazole	27220-47-9	150	Gemfibrozil	25812-30-0	4500
Enrofloxacin	93106-60-6	3090	Gendenafil	147676-66-2	3000
Eprazinone	10402-90-1	300	Glibenclamide	10238-21-8	4800
Erythromycin	114-07-8	240	Glimepiride	93479-97-1	2400
Estazolam	29975-16-4	60	Glipizide	29094-61-9	3000
Estradiol	50-28-2	1200	Glycopyrronium	740028-90-4	900
Estradiol benzoate	50-50-0	600	Griseofulvin	126-07-8	450
Estriol	50-27-1	60	Guaifenesin	93-14-1	2400
Estrone	53-16-7	30	Haloperidol	52-86-8	1620
Ethinyl estradiol	57-63-6	30	Homatropine	87-00-3	150
Ethisterone	434-03-7	600	Homosildenafil	642928-07-2	1350
Ethoxybenzamide	938-73-8	600	Hydralazine	86-54-4	450
Ethylestrenol	965-90-2	30	Hydrochlorothiazide	58-93-5	600
Etodolac	41340-25-4	600	Hydrocortisone	50-23-7	750
Etofibrate	31637-97-5	3000	Hydroxyacetildenafil	147676-56-0	600
Famotidine	76824-35-6	750	Hydroxyhomosildenafil	139755-85-4	1200
Fenbufen	36330-85-5	1875	Hydroxythiohomosildenafil	479073-82-0	1650
Fenfluramine	458-24-2	375	Hydroxyvaridenafil	224785-98-2	1500
Fenofibrate	49562-28-9	150	Hydroxyzine	2192-20-3	900
Fenoterol	13392-18-2	750	Ibuprofen	15687-27-1	1200
Finasteride (Proscar)	98319-26-7	3000	Imidazosagatriazinone	139756-21-1	1200
Flavoxate	15301-69-6	900	Imipramine	50-49-7	60
Flibanserin	167933-07-5	3600	Indapamide	26807-65-8	2400
Fluconazole	86386-73-4	480	Indomethacin	53-86-1	1200
Flufenamic acid	530-78-9	4050	Isoniazid	54-85-3	302.4

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 6 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu\text{g/g}$ )

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Ketoconazole	65277-42-1	300	Metronidazole	443-48-1	900
Ketoprofen	22071-15-4	450	Mexiletine	31828-71-4	1500
Ketotifen fumarate	34580-14-8	60	Midazolam	59467-70-8	60
Lidocaine	137-58-6	60	Minocycline	10118-90-8	750
Lincomycin	154-21-2	1710	Minoxidil	38304-91-5	600
Liothyronine	6893-02-3	3600	Morphine	57-27-2	150
Lomefloxacin	98079-51-7	1500	Nalidixic acid	389-08-2	300
Lorazepam	846-49-1	300	Naloxone	465-65-6	384
Lorcaserin	616202-92-7	900	Naltrexone	16590-41-3	2370
Maprotiline	10262-69-8	150	Nandrolone	434-22-0	750
Mazindol	22232-71-9	1950	Naphazoline Hydrochloride	835-31-4	300
Meclizine	569-65-3	60	Naproxen	22204-53-1	900
Mefenamic acid	61-68-7	900	N-Desethylvardenafil	448184-46-1	3000
Melatonin	73-31-4	1200	N-Desmethylacetildenafil	147676-55-9	3000
Meloxicam	71125-38-7	4500	N-Desmethylsibutramine	168835-59-4	3000
Meperidine	57-42-1	150	N-Desmethylsildenafil	139755-82-1	3000
Mephenesin	59-47-2	150	N-Didesmethylsibutramine	84467-54-9	3000
Mephentermine	100-92-5	240	Nefopam	13669-70-0	300
Meprobamate	57-53-4	375	Nicametate	3099-52-3	2550
Metformin	657-24-9	300	Nicotine	54-11-5	60
Methamphetamine	537-46-2	750	Nifedipine	21829-25-4	600
Methandriol	521-10-8	2400	Nifuroxazide	965-52-6	540
Methandrostenolone	72-63-9	600	Nitrazepam	146-22-5	600
Methaqualone	72-44-6	900	Nitrofurantoin	67-20-9	450
Metharbital	50-11-3	750	Nitrofurazone	59-87-0	4410
Methimazole	60-56-0	300	Noracetildenafil	949091-38-7	300
Methyl DOPA-Sesquihydrate	41372-08-1	1620	Noraminyprine	519-98-2	2400
Methylprednisolone	83-43-2	750	Norethisterone	68-22-4	600
Methyltestosterone	58-18-4	600	Norfloxacin	70458-96-7	300
Metoclopramide	364-62-5	750	Norfludiazepam	2886-65-9	150
Metoprolol	51384-51-1	150	Norgestrel	6533-00-2	600

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Documents.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 7 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Norneosildenafil	371959-09-0	1000	Piperidenafil	224788-34-5	1500
Nortadalafil	171596-36-4	1500	Pirenzepine	28797-61-7	1350
Noscapine	128-62-1	300	Piroxicam	36322-90-4	600
Nylidrin	849-55-8	4500	Prazosin	19216-56-9	300
Ofloxacin	82419-36-1	1920	Prednisolone	50-24-8	1200
Omeprazole	73590-58-6	1200	Prednisone	53-03-2	750
Orlistat	96829-58-2	375	Prilocaine	721-50-6	750
Orphenadrine	83-98-7	300	Primidone	125-33-7	30
Oxeladin	468-61-1	120	Probenecid	57-66-9	900
Oxethazaine	126-27-2	150	Procaine	59-46-1	300
Oxybutynin	5633-20-5	4635	Progesterone	57-83-0	600
Oxymetholone	434-07-1	1050	Promethazine	60-87-7	300
Oxyphenbutazone	129-20-4	450	Propafenone	54063-53-5	2400
Oxyphencyclimine	125-53-1	75	Propantheline	298-50-0	3000
Oxytetracycline (OTC)	79-57-2	960	Propranolol	525-66-6	1350
Papaverine	58-74-2	1560	Propyphenazone	479-92-5	3000
Pentazocine	359-83-1	30	Quetiapine	111974-69-7	2400
Pentobarbital	76-74-4	150	Quinine	130-95-0	300
Pentoxifylline	6493-05-6	2400	Ranitidine	66357-59-3	600
Phenacetin	62-44-2	3600	Reserpine	50-55-5	1200
Phenazopyridine	94-78-0	750	Rifampin	13292-46-1	120
Phenformin	114-86-3	900	Rimonabant	168273-06-1	3000
Phenobarbital	50-06-6	900	Rosiglitazone	122320-73-4	3000
Phenolphthalein	77-09-8	600	Salbutamol	18559-94-9	37.5
Phentermine	122-09-8	1500	Salicylamide	65-45-2	600
Phentolamine	50-60-2	1500	Salicylic acid	69-72-7	900
Phenylbutazone	50-33-9	750	Santonin	481-06-1	450
Phenylephrine	59-42-7	2850	Scopolamine	6533-68-2	150
Phenylpropanolamine	14838-15-4	60	Secobarbital	76-73-3	900
Pioglitazone	111025-46-8	1200	Sibutramine	106650-56-0	1200
Piperiacetildenafil	147676-50-4	3000	Sildenafil	139755-83-2	1200

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 8 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 附錄

365項西藥定性分析測試項目及偵測極限(LOD)彙整表：

單位： ppm( $\mu$ g/g)

測試項目	CAS NO.	LOD	測試項目	CAS NO.	LOD
Simvastatin	79902-63-9	600	Tetracycline	60-54-8	750
Spironolactone	52-01-7	300	Tetramethylpyrazine	1124-11-4	2400
Stanozolol	10418-03-8	2100	Theobromine	83-67-0	600
Strychnine	57-24-9	900	Theophylline	58-55-9	600
Sulfadiazine	68-35-9	600	Thiodimethylsildenafil	856190-47-1	450
Sulfadimethoxine	122-11-2	750	Thiohomosildenafil	479073-80-8	450
Sulfamerazine	127-79-7	450	Thioridazine	50-52-2	300
Sulfamethazine	57-68-1	600	Thiosildenafil	479073-79-5	450
Sulfamethizole	144-82-1	600	Tiletamine	14176-49-9	300
Sulfamethoxazole	723-46-6	600	Timolol Maleate	26921-17-5	150
Sulfamethoxypyridazine	80-35-3	450	Tinidazole	19387-91-8	900
Sulfamonomethoxine	1220-83-3	4650	Tolbutamide	64-77-7	375
Sulfanilamide	63-74-1	375	Topiramate	97240-79-4	450
Sulfapyridine	144-83-2	2400	Trazodone hydrochloride	19794-93-5	3000
Sulfaquinoxaline	59-40-5	4740	Triamcinolone	124-94-7	900
Sulfathiazole	72-14-0	600	Triamcinolone acetonide	76-25-5	4800
Sulfinpyrazone	57-96-5	750	Triazolam	28911-01-5	150
Sulfisomidine	515-64-0	3000	Trimethoprim	738-70-5	1500
Sulfisoxazole	127-69-5	450	Tripolidine	486-12-4	60
Sulindac	38194-50-2	750	Uscnic acid	125-46-2	3600
Sulpiride	15676-16-1	1140	Vardenafil	224785-90-4	1800
Synephrine	94-07-5	450	Vardenafil analogue(Molecular weight312.37)	224789-21-3	1800
Tadalafil	171596-29-5	600	Verapamil	152-11-4	60
Terbinafine	91161-71-6	300	Xanthinol Niacinate	437-74-1	1050
Terfenadine	50679-08-8	450	Yohimbine	146-48-5	1500
Testosterone	58-22-0	600	Zolazepam HCl	31352-82-6	60
Testosterone propionate	57-85-2	3000	Zolpidem	82626-48-0	300
Tetracaine	94-24-6	600	--	--	--

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



## 測試報告

報告編號： PUG22401040

日期： 2022年05月11日

頁數： 9 of 9



生麗國際股份有限公司  
桃園市桃園區中正路1353號15樓

### 樣品照片

## PUG22401040



## PUG22401040



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com/en/Terms-and-Conditions/Terms-e-Document.aspx>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of Client's instructions, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.